Critical Care Pharmaceuticals Market Peaks at $1.7 Billion

New York, June 4, 2006 — The U.S. market for ethical pharmaceuticals in the critical care setting appears to have peaked at $1.7 billion in 2005 after an eight-year growth trend, according to Critical Care Pharmaceutical Markets: A Strategic Analysis, the latest market research from Kalorama Information.

Cost-containment efforts, including the increased substitution of generics for brand drugs, could actually cause a decline in the market, as critical care units do their part to curb overall hospital expenditures. Indeed, factors affecting the markets for pharmaceuticals in the critical care setting are complex, as elements of both cost containment and the ability to most effectively treat ICU cases have been in a state of conflict.

Moreover, the entire philosophy of critical care treatment appears to be undergoing major changes at this time, further complicating an assessment of the future of this market. Hospital policies are continually changing with regard to pharmaceutical use in critical care units, and pharmaceutical-based data collection and isolation on this segment are virtually non-existent.

Likewise, changes in the composition of critical care teams with the inclusion of critical care pharmacist—a relatively new approach to critical care pharmacy—also appears to have a significant downward effect on the use of pharmaceuticals in the CCUs.

“While our findings show that this market may never materialize into a major niche market, it remains a significant leveraging factor for market penetration and formulary acceptance for high-volume, high-margin branded pharmaceutical products,” notes Kenneth G. Krul, Ph.D., the report’s author.

Focusing on the specific needs and market applications of the critical care pharmaceuticals market, this report addresses the options and opportunities presented by the market as well as the factors associated with strategic development within the market.

Critical Care Pharmaceutical Markets provides pharmaceutical companies with a “field general’s” perspective of the market, including the market impact of trends in cost-containment programs, restricted formulary acceptance, clinical pharmacy and the growth of the generic drug population. It can be purchased directly from Kalorama Information by clicking http://www.kaloramainformation.com/pub/1189532.html. It is also available at MarketResearch.com.

About Kalorama Information
Kalorama Information, a division of MarketResearch.com, a leading provider of industry-specific research reports, publishes the latest in independent market research for the life sciences. For more information, contact Tom Ehart at 240-747-3014 or tehart@marketresearch.com, or visit www.KaloramaInformation.com.